October 14, 2026 | Korea’s First GLP-1 & Bio AI Push 💪

Issue #57 · October 14

View Archive | Subscribe | Partners With Us

From Members to Global: Covering the Entire Bio Industry

A New Chapter for K-Bio?

Happy Wednesday! Korea is making headlines with the approval of its first homegrown GLP-1 drug, a KRW 744.3 billion ADC licensing deal, and a new government initiative to advance AI in biotechnology. Plus, discover the latest developments in global partnerships, clinical trials, and biotech business growth. Read on for the latest from K-Bio🚀

THIS WEEK:

Korea's Industry Ministry, Food and Drug Ministry Join Forces on Bio AI

The Ministry of Trade, Industry and Energy and the Ministry of Food and Drug Safety are building a cooperation framework covering the full cycle of artificial intelligence in the biotechnology sector, from technology development through licensing to exports. — Seoul Economic Daily

South Korea's first homegrown GLP-1 drug approved, opening new era in obesity treatment

South Korea has produced its first homegrown new drug in the class of glucagon-like peptide-1 (GLP-1) receptor agonists, joining a global obesity treatment market that has reshaped the pharmaceutical industry. — The Herald Business

Novelty Nobility inks KRW 744.3 billion license deal with U.S. biotech for C-Kit targeted ADC ‘NN3201’

Novelty Nobility has finalized a licensing-out (L/O) agreement for ‘NN3201’ (development code), an antibody-drug conjugate (ADC) candidate targeting ‘c-Kit.’ — THE BIO

EDITOR'S NOTE

REAL INNOVATION GLOWS IN THE DARK

📢 Just 2 Weeks Left! BIOPLUS-INTERPHEX KOREA 2026

Are you ready to discover what's next in the global bio industry?

📅 October 28-30, 2026
📍 COEX, Seoul | Hall C (3F), THE PLATZ (2F) & Conference Rooms

Discover cutting-edge innovations, global insights, and exciting business opportunities with 300+ exhibitors from around the world!

Visit the exclusive KoreaBIO Members Lounge at THE PLATZ (2F) for networking and connections!

KoreaBIO MEMBER NEWS

Novotech to Acquire Agilex Biolabs, a Specialist Bioanalytical Laboratory

Bilix Wins Innovation Tiger 2026 with Bilirubin-Based Drug Candidate for Kidney Injury Prevention and Treatment

DT&CRO Expands GLP Testing Services with New Certifications for Phototoxicity and Multi-Ion Channel Testing

KoNECT and C&R Research Explore Clinical Development Collaboration Opportunities in Indonesia with 11 Pharmaceutical and Biotech Companies

C&R Research Named Among 2026 Global Top 50 CRO, Ranked 15th Among 2026 Top 25 APAC

C&R Research Accelerates Global Data CRO Business by Integrating Data and AI and Securing Global Medical Data Supply Chains

HUINNO and Yuhan Supply MEMO CUE Real-Time Patient Monitoring Solution to Dongkang Medical Center's Cardiology Department

👥 View More Members Companies

#Member #Benefits

The 21st Bio Networking Event

🗓️ November 16, 2026

✨ Free for member companies

👋 Non-Member Companies Welcome

▶Notice (Korean Only)

2026 4th CEO Golf Affinity

🗓️ November 12, 2026

⛳ Fostering collaboration among member companies and creating new business opportunities

▶Notice (Korean Only)

Here's what's happening across Korea's bio industry!

WHAT'S HAPPENING

KOREA GOES GLOBAL

∎ Celltrion nears additional contract with major U.S. PBM - Asiatoday
∎ Dong-A ST enters UAE with anemia-treatment biosimilar, launching Middle East push - The financial news
∎ Korea's GCCL signs MoU with LabConnect to expand global clinical trial collaboration - BioSpectrum Asia
∎ Korea's Lunit collaborates with US-based Discovery Life Sciences to expand AI-powered tissue analysis for biopharma research - BioSpectrum Asia
∎ L&C Bio signs exclusive U.S. supply deal for Re2O worth 82 billion won - The financial news
∎ Lotte Biologics expands US manufacturing partnership with Alvotech - The Korea Herald

INNOVATION & TRENDS

∎ Dt&CRO bolsters competitiveness as a full-cycle new drug development CRO, widens academia and industry collaboration - THE BIO
∎ GS Caltex wins London awards for carbon capture campaign - The Korea Herald
∎ HanAll adds topical minoxidil to growing hair loss drug portfolio - KBR
∎ Big firms take 77% of Korean pharma profits - Aju Press
∎ Big pharma courts Korea startups for AI drug design and brain disease cures - Chosun Biz
∎ “Hydrogen Made from Trash—Is It Really ‘Eco-Friendly’?” - The financial news

GROWTH & PERFORMANCE

∎ 23 Biotech Companies Pitch for Funding at Saudi Arabia’s LSIF 2026 - LA Times
∎ AbClon: “China’s Henlius Biotech launches ‘AC101’ trials in colorectal cancer and ADC-resistant breast cancer” - THE BIO
∎ Celltrion rolls out asthma treatment ‘Omlyclo,’ marking first ‘omalizumab’ biosimilar in U.S. - THE BIO
∎ GI Innovation starts Japan phase 2 trial of allergy drug - The Korea Herald
∎ Keytruda Biosimilar Enters U.S. FDA Review for First Time, Sparking Race for KRW 40 Trillion Market - The Asia Business Daily
∎ Samsung Biologics Nears $2 Billion PolyPeptide Takeover - Business Korea

📰 View Latest KoreaBIO News

WHAT'S COMING UP?

Creating New Opportunities Together!

[KoreaBIO x Zoetis] Open Innovation Challenge

Application Deadline: October 16, 2026 Closing Soon!

Discover. Connect. Build What’s Next! (Pre-registration Now Open)

BIOPLUS-INTERPHEX KOREA 2026

October 28-30, 2026

Learn More? [Visit our Website]

New here? Join 2,700+ insatiably curious readers [Sign up here]

Missed Something? Check up on [Past Issues]

Korea Biotechnology Industry Organization (KoreaBIO)

700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

수신거부 Unsubscribe